Filter Your Search

Clinical Trial Search

Keyword

Principal Investigator

Condition/Disease

For Healthcare Professionals

At Henry Ford Health System we serve a triple mission of Clinical Care, Research and Education. It is this triple mission that drives how we care for our patients, how we interact with referring physicians, how we work to innovate healthcare and how we train future physicians.

Learn More

Clinical Trials Search Results

MK-7339-010 - A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Principal Investigator:Clara Hwang, MD

Status: Open

Contact Phone: (313) 916-8862

Contact Email: CTOResearch@hfhs.org

Read More

MK7123-034: A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

Principal Investigator:Ding Wang, MD

Status: Open

Contact Phone: (313) 916-7453

Contact Email: CTOResearch@hfhs.org

Read More

Mirati-516: A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Principal Investigator:Ding Wang, MD

Status: Accepting Participants

Contact Phone: (313) 916-1784

Contact Email: CTOResearch@hfhs.org

Read More

PCYC-1128-CA: A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Principal Investigator:Ding Wang, MD

Status: Accepting Participants

Contact Phone: (313) 916-7453

Contact Email: CTOResearch@hfhs.org

Read More

SWOG 1802 Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Principal Investigator:Ding Wang, MD

Status: Accepting Participants

Contact Phone: (313) 916-8862

Contact Email: CTOResearch@hfhs.org

Read More

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants With Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

Principal Investigator:Clara Hwang, MD

Status: Open

Contact Phone: (313) 916-8862

Contact Email: CTOResearch@hfhs.org

Read More

PROpel D081SC00001 - A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer

Principal Investigator:Clara Hwang, MD

Status: Open

Contact Phone: (313) 916-8862

Contact Email: CTOResearch@hfhs.org

Read More

«
‹
1
2
›
»

Page 1 of 2 | Results 1 - 10 of 18